Michael E. Morgan

发表

Discovery and structure-activity relationship of (1R)-8-chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine (Lorcaserin), a selective serotonin 5-HT2C receptor agonist for the treatment of obesity.

Brian M. Smith, F. Menzaghi, P. Dosa, 2008, Journal of medicinal chemistry.

Discovery of a novel trans-1,4-dioxycyclohexane GPR119 agonist series.

S. H. Kim, Michael E. Morgan, Robert M. Jones, 2015, Bioorganic & medicinal chemistry letters.

Discovery and optimization of 5-fluoro-4,6-dialkoxypyrimidine GPR119 agonists.

S. H. Kim, Michael E. Morgan, K. Whelan, 2014, Bioorganic & medicinal chemistry letters.

Discovery of a second generation agonist of the orphan G-protein coupled receptor GPR119 with an improved profile.

F. Du, C. Sage, Albert S. Ren, 2012, Bioorganic & medicinal chemistry letters.

Nelotanserin, a Novel Selective Human 5-Hydroxytryptamine2A Inverse Agonist for the Treatment of Insomnia

R. Luthringer, C. Anderson, Michael E. Morgan, 2010, Journal of Pharmacology and Experimental Therapeutics.

Discovery of a lead series of potent benzodiazepine 5-HT2C receptor agonists with high selectivity in functional and binding assays.

C. Sage, Albert S. Ren, Michael E. Morgan, 2019, Bioorganic & medicinal chemistry letters.

Discovery of 1a,2,5,5a-tetrahydro-1H-2,3-diaza-cyclopropa[a]pentalen-4-carboxamides as potent and selective CB2 receptor agonists.

I. Gaidarov, Michael E. Morgan, K. Whelan, 2015, Bioorganic & medicinal chemistry letters.

Investigating interactions between phentermine, dexfenfluramine, and 5-HT2C agonists, on food intake in the rat

C. Sage, Michael E. Morgan, K. Whelan, 2014, Psychopharmacology.

Discovery of 2-(((1r,4r)-4-(((4-Chlorophenyl)(phenyl)carbamoyl)oxy)methyl)cyclohexyl)methoxy)acetate (Ralinepag): An Orally Active Prostacyclin Receptor Agonist for the Treatment of Pulmonary Arterial Hypertension.

John W. Adams, A. Blackburn, I. Gaidarov, 2017, Journal of medicinal chemistry.

Discovery of a new series of potent prostacyclin receptor agonists with in vivo activity in rat.

John W. Adams, Michael E. Morgan, Yunqing Shi, 2015, Bioorganic & medicinal chemistry letters.

Discovery of fused bicyclic agonists of the orphan G-protein coupled receptor GPR119 with in vivo activity in rodent models of glucose control.

C. Sage, B. Fioravanti, Albert S. Ren, 2011, Bioorganic & medicinal chemistry letters.

Design of a new series of potent and selective beta-3 adrenergic receptor (β3-AdrR) antagonists for the treatment of acute decompensated heart failure

John W. Adams, C. Sage, Michael E. Morgan, 2022, Results in Chemistry.

APD791, 3-Methoxy-N-(3-(1-methyl-1H-pyrazol-5-yl)-4-(2-morpholinoethoxy)phenyl)benzamide, a Novel 5-Hydroxytryptamine 2A Receptor Antagonist: Pharmacological Profile, Pharmacokinetics, Platelet Activity and Vascular Biology

John W. Adams, D. Connolly, Michael E. Morgan, 2009, Journal of Pharmacology and Experimental Therapeutics.

Anti-thrombotic and vascular effects of AR246686, a novel 5-HT2A receptor antagonist.

John W. Adams, D. Connolly, P. Dosa, 2008, European journal of pharmacology.

(7-Benzyloxy-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl)acetic Acids as S1P1 Functional Antagonists.

A. Blackburn, I. Gaidarov, S. H. Kim, 2014, ACS medicinal chemistry letters.

Fused tricyclic indoles as S1P₁ agonists with robust efficacy in animal models of autoimmune disease.

D. Sengupta, Michael E. Morgan, K. Whelan, 2012, Bioorganic & medicinal chemistry letters.

Lorcaserin, a Novel Selective Human 5-Hydroxytryptamine2C Agonist: in Vitro and in Vivo Pharmacological Characterization

Brian M. Smith, F. Menzaghi, Michael Martin, 2008, Journal of Pharmacology and Experimental Therapeutics.

morpholinoethoxy ) phenyl ) benzamide ( APD 791 ) : AHighly Selective 5-Hydroxytryptamine 2 A Receptor Inverse Agonist for the Treatment of Arterial Thrombosis

John W. Adams, D. Connolly, P. Dosa, 2010 .

Discovery of the first potent and orally efficacious agonist of the orphan G-protein coupled receptor 119.

William Thomsen, B. Fioravanti, Albert S. Ren, 2008, Journal of medicinal chemistry.

Discovery of APD334: Design of a Clinical Stage Functional Antagonist of the Sphingosine-1-phosphate-1 Receptor.

A. Blackburn, David Mills, I. Gaidarov, 2014, ACS medicinal chemistry letters.

Pharmacokinetics and Tolerability of Lorcaserin in Special Populations: Elderly Patients and Patients with Renal or Hepatic Impairment.

C. Anderson, Michael E. Morgan, Matilde Sánchez, 2017, Clinical therapeutics.

Investigating interactions between phentermine, dexfenfluramine, and 5-HT2C agonists, on food intake in the rat

C. Sage, Michael E. Morgan, K. Whelan, 2014, Psychopharmacology.

P-179 Safety, Pharmacokinetics and Pharmacodynamics of Etrasimod (APD334), an Oral Selective S1P Receptor Modulator, After Dose-Escalation, in Healthy Volunteers

L. Peyrin-Biroulet, Michael E. Morgan, Matilde Sanchez-Kam, 2017 .

P-180 Etrasimod (APD334), a Potent, Selective, Oral S1P Receptor Modulator with Autoimmune Disease-Modifying Activity Exhibiting Favorable PK/PD Properties in Healthy Volunteers

J. Panés, Michael E. Morgan, Matilde Sanchez-Kam, 2017 .

Single- and Multiple-dose Pharmacokinetics of a Lorcaserin Extended-release Tablet.

J. Ferry, A. Kristensen, Michael E. Morgan, 2016, Clinical therapeutics.